Literature DB >> 3084125

Plasma apoproteins and the severity of coronary artery disease.

S P Sedlis, K B Schechtman, P A Ludbrook, B E Sobel, G Schonfeld.   

Abstract

Plasma levels of lipids, lipoproteins, and apoproteins in 281 patients undergoing cardiac catheterization were correlated with the incidence and severity of coronary artery disease (CAD) to determine if measurements of apoprotein levels are more predictive of the presence and severity of CAD than the corresponding levels of lipoprotein lipids. In 156 men with CAD among 194 men in the study the only variable other than age that correlated with the severity of CAD, defined by the number of lesions and percent stenosis, was the ratio of apoprotein AI to apoprotein B (r = .1908, p less than .03). The ratio of apoprotein AI to apoprotein B was a more accurate predictor of the severity of CAD than was the ratio of the corresponding high-density to low-density lipoprotein levels (coefficients of partial determination of .07 and .035; p less than .001 and p less than .07, respectively). Multivariate analysis confirmed the independent effect of the ratio of apoprotein AI to apoprotein B on the severity of CAD even after adjustments were made for lipid levels, age, presence of hypertension or diabetes, and therapy with beta-blockers or diuretics. Among men with total occlusion of a coronary artery apoprotein E and apoprotein B levels were significantly higher than in control subjects with a similar extent of CAD (p less than .03). The lipid profiles of the 37 women with CAD were very different from those of the men.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084125     DOI: 10.1161/01.cir.73.5.978

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

Review 1.  The relationship between high density lipoprotein subclass profile and apolipoprotein concentrations.

Authors:  L Tian; M Fu
Journal:  J Endocrinol Invest       Date:  2011-06       Impact factor: 4.256

2.  Apolipoprotein A and prognosis after myocardial infarction in non-diabetic men.

Authors:  H Pollak; O Arnoldner; W Enenkel; M Fischer; D Trubert-Exinger
Journal:  Klin Wochenschr       Date:  1991-01-04

3.  Serum Apo A-1 and Its Role as a Biomarker of Coronary Artery Disease.

Authors:  Salma Rahim; Hafez Mohammad A Abdullah; Yousaf Ali; Uzma I Khan; Waqas Ullah; Muhammad A Shahzad; Muhammad Waleed
Journal:  Cureus       Date:  2016-12-24

4.  Effects of treatment with verapamil SR and captopril on the lipid profile of hypertensive patients.

Authors:  M Catalano; C Cislaghi; G Carzaniga; A Aronica; R Seregni; A Libretti
Journal:  Drugs       Date:  1992       Impact factor: 9.546

5.  The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, Minnesota. II. Regression relationships with concomitants.

Authors:  S L Reilly; R E Ferrell; B A Kottke; C F Sing
Journal:  Am J Hum Genet       Date:  1992-12       Impact factor: 11.025

6.  Systemic arterial hypertension and coronary atherosclerosis. Observations in survivors of a first myocardial infarction.

Authors:  G Sánchez Torres; C Posadas Romero; C Tena Tamayo; I Hernández Santamaría
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease.

Authors:  M Barbir; D Wile; I Trayner; V R Aber; G R Thompson
Journal:  Br Heart J       Date:  1988-11

Review 8.  Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies.

Authors:  Katarzyna Rygiel
Journal:  Curr Cardiol Rev       Date:  2018-03-14

9.  Uncontrolled hypertension in patients with type 2 diabetes: What are the correlates?

Authors:  Soghra Rabizadeh; Bahareh Gholami; Shiva Mahmoudzadeh Kani; Armin Rajab; Hossein Farrokhpour; Alireza Esteghamati; Manouchehr Nakhjavani
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-08-21       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.